Titlebook: Dose Finding in Drug Development; Naitee Ting Book 2006 Springer-Verlag New York 2006 Maxima.Radiologieinformationssystem.clinical trial.c

使增至最大

https://doi.org/10.1007/978-94-011-9597-3, Phase I clinical investigation includes studies of drug metabolism, bioavailibility, dose ranging, and multiple dose. For doseescalation studies, clinical researchers usually start with lowdose which is unlikely to present any harmful effects to subjects.

CLAY

良心

,Dose Finding in Oncology—Parametric Methods,orresponds to the highest dose associated with a tolerable level of toxicity. More precisely, the MTD γ is defined as the dose expected to produce some degree of medically unacceptable, dose limiting toxicity (DLT) in a specified proportion θ of patients (see Gatsonis and Greenhouse, 1992). Hence, we have

留戀

Multiple Comparison Procedures in Dose Response Studies,he problem of identifying the maximum safe dose (MaxSD) in Section 11.3. Examples are given in Section 11.4 followed by some extensions in Section 11.5. The paper concludes with a discussion in Section 11.6.

CON

Power and Sample Size for Dose Response Studies,, Phase I clinical investigation includes studies of drug metabolism, bioavailibility, dose ranging, and multiple dose. For doseescalation studies, clinical researchers usually start with lowdose which is unlikely to present any harmful effects to subjects.

常到

Dose-Finding Studies in Phase I and Estimation of Maximally Tolerated Dose,t of marketed drugs has been improved, in some cases, by postmarketing label changes, which aim to optimize the dosage regimen for the indicated populations (Cross et al., 2002). These postmarketing changes in the label may reflect the quality of drug development, regulatory review and postmarketing surveillance.

fastness

,Dose-Finding in Oncology—Nonparametric Methods,alation steps have decreasing relative increments (100, 65, 50, 40, and 30% thereafter). Toxicity in oncology trials is graded using the National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0 (available online from the Cancer Therapy Evaluation Program website http://ctep.cancer.gov).

indemnify

,Analysis of Dose–Response Studies—Modeling Approaches,ffect on the outcome under consideration, the so called proof-of-activity (PoA), sometimes also referred to as a proof-of-concept (PoC), and selecting a dose (or doses) that appears to be efficacious and safe, for further development in Phase III, the so-called dose-finding step.

deadlock

,Partitioning Tests in Dose–Response Studies with Binary Outcomes,ways of controlling the familywise error rate (FWER) strongly should be well specified prior to unmasking the study data. In many cases, these prespecification need to be clearly communicated with regulatory agencies for mutual agreement.

美學